Martin Shkreli Still Hasn’t Dropped the Price of Daraprim
A 30-day supply costs over $27,000.
A few weeks back, pharma CEO Martin Shkreli was the focus of a massive international rage wave that tore across the world after he raised the price of Daraprim from $13.50 a pill to $750 after acquiring its marketing rights from Impax Laboratories. Shkreli defended the massive price hike by saying, “If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don’t think that that should be a crime.”
After the PR disaster, Shkreli agreed to lower the price, telling ABC News, “We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.” But, two weeks later, a 30-day supply of 30 pills of Daraprim still costs a whopping $27,206. Every day the price stays up, vulnerable people lose access to the life-saving drug.
Daraprim is a treatment for toxoplasmosis, a parasitic condition that can kill people with compromised immune systems, including pregnant women, unborn children, and AIDS patients. Currently, in Canada, Daraprim costs $5.12 a pill and in the UK, $1.32.
(H/T Tech Insider)